Literature DB >> 33430704

Assessing the Angiogenic Efficacy of Pleiotrophin Released from Injectable Heparin-Alginate Gels.

Isobel Rountree1, Collin Polucha1, Kareen L K Coulombe1, Fabiola Munarin1.   

Abstract

With this work, we design alginate-based hydrogels for therapeutically directing revascularization and repair processes in vivo. We immobilize pleiotrophin (PTN) in injectable hydrogel formulations as the target factor to stimulate proangiogenic responses in endothelial cells. The optimized heparin-alginate/chitosan hydrogels, produced by internal crosslinking with calcium carbonate, show good biocompatibility and injectability and allow controlling the release of immobilized proteins in the subcutaneous tissue over a period of 7 days. In vitro assays, performed with translational human induced pluripotent stem cell-derived endothelial cells, and the in vivo Matrigel plug assay are conducted to demonstrate the angiogenic effects of PTN on endothelial cells. Our results indicate that PTN stimulates endothelial cell morphogenesis in vitro and the migration of endothelial cells and macrophages as soon as 4 days after injections of the developed hydrogels, promoting the formation of structures similar to the healthy granulation tissue, which is an indicator of healing in ischemic wounds. These studies provide the rationale for further investigating this novel therapeutic for pursuing increased vascular density for efficient regeneration of ischemic tissues, by leveraging the host endothelial cell population to initiate angiogenic and reparative processes in vivo. Impact statement Localized, sustained, and controlled delivery of angiogenic factors is crucial for enabling the formation of novel vascular networks in ischemic tissues. This study describes the development of an injectable heparin-alginate/collagen hydrogel for controlling the in vivo release and bioactivity of pleiotrophin (PTN), a heparin-binding factor with significant angiogenic activity. We demonstrate that PTN promotes angiogenesis in an in vitro model of hypoxia and in preclinical subcutaneous models. These results advance our understanding of PTN function in guiding therapeutic angiogenesis and are critical to inform the development of novel translational strategies for ischemic tissue repair and regeneration.

Entities:  

Keywords:  alginate; angiogenesis; growth factors delivery; heparin; hydrogels; pleiotrophin

Mesh:

Substances:

Year:  2021        PMID: 33430704      PMCID: PMC8219190          DOI: 10.1089/ten.TEA.2020.0335

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   4.080


  47 in total

Review 1.  Coordinating cell behaviour during blood vessel formation.

Authors:  Ilse Geudens; Holger Gerhardt
Journal:  Development       Date:  2011-09-28       Impact factor: 6.868

Review 2.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

3.  Sustained release of vascular endothelial growth factor from calcium-induced alginate hydrogels reinforced by heparin and chitosan.

Authors:  K W Lee; J J Yoon; J H Lee; S Y Kim; H J Jung; S J Kim; J W Joh; H H Lee; D S Lee; S K Lee
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

4.  Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury.

Authors:  A Takeda; H Onodera; A Sugimoto; Y Itoyama; K Kogure; H Rauvala; S Shibahara
Journal:  Neuroscience       Date:  1995-09       Impact factor: 3.590

Review 5.  Growth factors as active participants in carcinogenesis: a perspective.

Authors:  J Halper
Journal:  Vet Pathol       Date:  2010-01       Impact factor: 2.221

6.  Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP)-43 mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons.

Authors:  Hiroko Yanagisawa; Yukari Komuta; Hitoshi Kawano; Masashi Toyoda; Kazunori Sango
Journal:  Neurosci Res       Date:  2009-10-13       Impact factor: 3.304

Review 7.  Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis.

Authors:  Pablo Perez-Pinera; James R Berenson; Thomas F Deuel
Journal:  Curr Opin Hematol       Date:  2008-05       Impact factor: 3.284

Review 8.  Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.

Authors:  Celia González-Castillo; Daniel Ortuño-Sahagún; Carolina Guzmán-Brambila; Mercè Pallàs; Argelia Esperanza Rojas-Mayorquín
Journal:  Front Cell Neurosci       Date:  2015-01-08       Impact factor: 5.505

9.  Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.

Authors:  Yu Shi; Yi-Fang Ping; Wenchao Zhou; Zhi-Cheng He; Cong Chen; Bai-Shi-Jiao Bian; Lin Zhang; Lu Chen; Xun Lan; Xian-Chao Zhang; Kai Zhou; Qing Liu; Hua Long; Ti-Wei Fu; Xiao-Ning Zhang; Mian-Fu Cao; Zhi Huang; Xiaoguang Fang; Xiuxing Wang; Hua Feng; Xiao-Hong Yao; Shi-Cang Yu; You-Hong Cui; Xia Zhang; Jeremy N Rich; Shideng Bao; Xiu-Wu Bian
Journal:  Nat Commun       Date:  2017-06-01       Impact factor: 14.919

10.  Release kinetics of the model protein FITC-BSA from different polymer-coated bovine bone substitutes.

Authors:  Julian Lommen; Lara Schorn; Alexis Landers; Henrik Holtmann; Karin Berr; Norbert R Kübler; Christoph Sproll; Majeed Rana; Rita Depprich
Journal:  Head Face Med       Date:  2019-11-11       Impact factor: 2.151

View more
  2 in total

1.  Bio-inspired green light crosslinked alginate-heparin hydrogels support HUVEC tube formation.

Authors:  Patrick N Charron; Luis M Garcia; Irfan Tahir; Rachael A Floreani
Journal:  J Mech Behav Biomed Mater       Date:  2021-10-28

2.  Heparin-modified alginate microspheres enhance neovessel formation in hiPSC-derived endothelial cells and heterocellular in vitro models by controlled release of vascular endothelial growth factor.

Authors:  Fabiola Munarin; Carly Kabelac; Kareen L K Coulombe
Journal:  J Biomed Mater Res A       Date:  2021-03-17       Impact factor: 4.854

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.